A Single Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1293 and to Compare Its Pharmacologic Properties to Those of Another Basal Insulin in Subjects With Type I Diabetes

Trial Profile

A Single Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1293 and to Compare Its Pharmacologic Properties to Those of Another Basal Insulin in Subjects With Type I Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Aug 2016 According to a Merck media release, the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293 (Insulin glargine) for the treatment of people with type 1 and type 2 diabetes, data from this study supported the application. The NDA was filed through the 505(b)(2) regulatory pathway.
    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Mar 2015 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top